HLS Therapeutics Inc. (TSX:HLS)

Market Cap	143.55M +5.7%
Revenue (ttm)	77.81M -1.8%
Net Income	-14.36M
EPS	-0.45
Shares Out	31.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,100
Average Volume	6,734
Open	4.570
Previous Close	4.640
Day's Range	4.490 - 4.590
52-Week Range	4.220 - 5.765
Beta	0.83
RSI	52.94
Earnings Date	May 15, 2026

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Craig Millian
• Employees: 85
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: HLS

Financial Performance

In 2025, HLS Therapeutics's revenue was $55.50 million, a decrease of -1.98% compared to the previous year's $56.62 million. Losses were -$12.43 million, -36.76% less than in 2024.

Financial numbers in USD